4. Депрессия при болезни паркинсона как ведущий фактор

МС №4 3013 Неврология/Ревматология
4. Депрессия при болезни паркинсона как ведущий фактор ухудшения качества жизни
пациентов: патофизиология, диагностика, терапия
М.Р. Нодель, к.м.н., Клиника нервных болезней Первого МГМУ им. И.М. Сеченова
Литература
1. Яхно Н.Н. Невро-психиатрия. Место неврологов. X Всероссийский съезд неврологов с международным
участием. Материалы съезда./ Н. Новгород. 2012. С.698.
2. Яхно Н.Н. Захаров В.В., Нодель М.Р. Когнитивные и другие нервно-психические нарушения болезни
Паркинсона. // В кн. Болезни движений: медицинские и социальные аспекты. /под. ред. Е.И. Гусева, А.Б.
Гехт. М. 2010. С.95–97.
3. Нодель М.Р., Яхно Н.Н. Нервно-психические нарушения болезни Паркинсона. //Неврология.
Нейропсихиатрия. Психосоматика. 2009. №2. C.3–8.
4. Нодель М.Р. Недвигательные нарушения болезни Паркинсона. //Доктор.Ру. Неврология. 2009. №4. C.12–
16.
5. Левин О.С. Болезнь Паркинсона как нейропсихиатрическое заболевание. //Руководство для врачей по
материалам II Национального конгресса по болезни Паркинсона и расстройствам движений (под ред. С.Н.
Иллариошкина, О.С. Левина). М. 2011. С.99–104.
6. М.Р. Нодель. Клинические особенности и лечение недвигательных нарушений болезни Паркинсона.//
Медицинский совет. -2012.-N 4.-С.30-36.
7. D.Aarsland, Marsh L., A.Schrag . Neuropsychiatric symptoms in Parkinsons Disease. //Mov.Dis.-2009Vol.24(15).-P.2175-86.
8. OSullivan S.S., Williams D.R., Gallarher D.A., et,.al. Non motor symptoms as presenting complaints in
Parkinsons disease: a clinicopathological study. //Mov.Dis.-2008-Vol.23-P.101-106.
9.Shrag A., Jahanshahi M., Quinn N.P. What contributes to quality life in patients with Parkinsons
disease?//J.Neurol.Neurosurg.Neuropsych.-2000.-Vol.69.-P.308-312.
10.Scaravilli T., Gasparoli E., Rinaldi F. et.al. Health related quality of life in Parkinsons disease. //
J.Nourol.Neurosurg.Psychiat.-2003.-74 (2)-P.163-169.
11.Mc Kinlay A., Grace R.C., Dalrymple-Alford J.C., et.al. A profile of neuropsychiatric problems and their
relationship to quality of life for Parkinsons disease. //Park. and Relat. disord.-2008.-Vol.14.-P.37-42
12.Cole S. A., Woodard J. L. , Juncos J. L. , et. al. Depression and disability in Parkinsons disease. // J.
Neuropsychiatry Clin. Neurosci. -1996. - Vol. 8. - P. 20-25.
13.Shrag A., Jahanshahi M., Quinn N.P. What contributes to depression in Parkinsons disease?// Psychol.Med.2001.-Vol.31.-P.65-73.
14.S.E.Starkstein, Preziosi T.J., Robinson R.G. Sleep disorders, pain and Parkinsons disease depression in
Parkinsons disease. //Eur. Neurol.-1991.-Vol.31(6).-P.352-355.
15.Norman S., Troster A.I., Fields J.A., et.al. Effects of depression and Parkinsons disease on cognitive
functioning. . // J.Neuropsychiatr.Clin. Neurosci.-2002.-Vol.14(1).-P.31-36.
16.М.Р. Нодель. Депрессия при болезни Паркинсона. //Неврология.
Нейропсихиатрия.Психосоматика.-2010.-N4.- C.11-17.
17.Dooneief G., Mirabello E., Bell K., et.al. An estimate of the incidence of depression in idiopathic Parkinsons
disease. //Arch.Neurol.-1992.-Vol.49(3).-P.305-307.
18.Lemke M.R. Depressive symptoms in Parkinsons disease. //Eur. J.of Neurol.-2008.-Vol.15(Suppl.1).-P.21-25.
19.Gotham A. M., Brown R. C. , Marsden C. D. Depression in Parkinsons disease: a quantitative and qualitative
analysis in Parkinsons disease. // J. Neuropsychiatry Clin. Neurosci. -1996. - Vol. 8. - P. 20-25.
20.Mayberg H.S., Starkstein S.E., Sadzot B., et.al. Selective hypometaboloism in the inferior frontal lobe in
depressed patients with Parkinsons Disease. //Ann.Neurol.-1990.-Vol.28(1)-P.57-64.
21.Matsiu H., Nishinaka K., Oda M., et.al. Depression in Parkinsons disease:diffusion tensor imaging study.
//J.Neurol.-2007.-Vol.254.-P.1170-1173.
22. Chaudhuri K.R., Schapira A. H.V. Non-motor symptoms of Parkinsons disease: dopaminergic pathophysiology
23. R.Mayeux, Y.Stern, I.Cote , J.B. Williams. Altered serotonin metabolism in depressed patients with Parkinsons
Disease. //Neurol.-1984.-Vol.34(5).-P.642-646.
24. M.Yamomoto. Depression in Parkinsons Disease : its prevalence, diagnosis, and neurochemical background.
//J.Neurol.-2001.-Vol.248 (Suppl
25. P.G.Frisina, V.Haroutunian, L.S.Libow. The neuropatological basis for depression in Parkinsons Disease.
//Park. and Relat.Dis.-2009.-Vol.15.-P.144-148.
26. Remy P., M.Doder, A.Lees, et.al. Depression in Parkinsons Disease: loss of dopamine and noradrenaline
innervation in the limbic system. //Brain.-2005.-Vol.128.-P.1314-1322.
27. M.Guttman, M.Torti, J.Warsh et.al. Are brain serotonin transporter levels decreased in depressed patients with
Parkinsons Disease? //J.Neurol.Sci-2006.-Vol.248-P.299.
28.Alex K.D., Pehek E.A. Pharmacologic mechanisms of serotoninergic regulation of dopamine neurotransmission.
// Pharmacol. Ther.-2007.-Vol.113-P.296-320.
29.F.Fang, Q.Xu, Y.Park, X.Huang, et.al. Depression and the subsequent risk of Parkinsons disease in the NINAARP Diet and Health Study. //Mov.Dis.-2010-Vol.25.-N9.-P.1157-1162.
30.Braak H., Del Tredici K., Rub U., et. al. Staging of brain pathology related to sporadic Parkinsons disease.
//Neurology Aging - 2003.-Vol.24.-P.197-210.
31.Santamaria J. , Tolosa E. , Valles A. Parkinsons disease with depression: a possible subgroup of idiopathic
parkinsonism. //Neurology. -1986. - Vol. 36. - P. 1130-1133.
32.A.F.Leentjens, R.Lousberg, F.R.Verhey. Markers for depression in Parkinsons Disease. //Acta Psych.Scand.2002.-Vol.106(3)-P.196-201.
33.Cummings J. L. Depression and Parkinsons disease: a review. // Am. J. Psychiatry-1992. - Vol. 149. - P. 443454.
34.E.Tanberg, J.P.Larsen, D.Aarsland et.al. Risk factors for depression in Parkinsons Disease. //Arch. Neurol.1997.-Vol.54(5).-P.625-630.
35.A.Rojo , M.Agullar , M.T. Garolera , et.al. Depression and Parkinsons disease: clinical correlates and outcome.
//Park. Relat Dis.- 2003.-Vol.10(1).-P.23-28.
36. Cole S.A., Woodard J.L., Juncos J.L., et.al. Depression and disability in Parkinsons disease.
//J.Neuropsychiatr.Clin. Neurosci-1996.-Vol.8(1).-P.20-25.
37. C.Becker, G.P.Brobert, S.Johansson et.al. Risk of incident depression in patients with Parkinsons disease in the
UK. //Eur.J.of Neurol.-2011.-Vol.18.-P.448-453.
38. A.Althaus, O.A.Becker, A.Spottke, et.al. Frequency and treatment of depressive symptoms in a Parkinsons
Disease registry. //Park. and Relat. disord.-2008.-Vol.14.-P.626-632
39.Y.Cheng, C.Liu, C.Mao et.al. Social support plays a role in depression in Parkinsons disease: a cross-section
study in a Chinese cohort. //Park. аnd Related Dis.-2008.-Vol.14.-P.43-45.
40.Янакаева Т. А. Сравнительный анализ когнитивных и аффективных расстройств при дисциркуляторной
энцефалопатии, болезни Паркинсона и болезни Альцгеймера. Диссертация …канд. мед. наук. – М., 1999.
41.E.Starkstein, Petracca G., Chemerinski E., et.al. Depression in classic versus akinetic-rigid Parkinsons disease.
//J.Neur. Ment.Dis.-1998.-Vol.13(1).P.-29-33.
42. F.Liebermann. Depression in Parkinsons Disease- a review. //Acta Neurol.Scand.-2006.-Vol.113-P.1-8.
43.Lemke M.R. Depressive symptoms in Parkinsons disease. //Eur.J.of Neurol.-2008.-Vol.15(Suppl.1).-P.21-25.
44. American Psychiatric Association. Diagnostic and Statistical Manual of mental Disorders, 4-th ed. Washington,
ВС:APA Press 2000.
45. J.Reiff, N.Schmidt, B.Riebe, et.al. Subthreshold depression in Parkinsons disease. //Mov.Dis.-2011-Vol.26N9.-P.1741-1744.
46.S.E.Starkstein , M.Merello, R.Jorge , et.al. A validity study of depressive syndromes in Parkinsons disease. //
Mov.Dis.-2008-Vol.23-P.538-546.
47.T.Inoue, M.Kitagawa, T.Tanaka, et.al. Depression and major depressive disorder in patients with Parkinsons
disease. // Mov.Dis.-2010-Vol.25-N1-P.44-49.
48.Barone P., Antonini A., Colosimo C., et.al. The PRIAMO study: a multicenter assessment of nonmotor
symptoms and their impact on quality of life in Parkinson disease. //Mov.Dis.-2009.-Jun 9.-P.215-216.
49. Shrag A., Barone P., Brown R.G. et.al. Depression rating scales in Parkinson disease: critique and
recommendations. //Mov.Dis.-2007.-Vol.22.-P.1077-1192.
50.Dujardin K., Sockeel P., Devos D., et.al. Characteristic of apathy in Parkinsons disease. // Mov.Dis.-2007.Vol.22.-P.778-784.
51. М.Р. Нодель. Утомляемость при болезни Паркинсона и ее коррекция агонистом дофаминовых
рецепторов прамипексолом //Неврология. Нейропсихиатрия.Психосоматика.-2011.-N 4.- C.22-26.
52.Barone P et al. Depression and antidepressant use in Parkinson’s disease: Results from the PRODEST-PD study.
Abstract P1122 poster presented at 11th Congress of EFNS, Brussels, 26 Aug 2007.
53.Weintraub D., Morales K.H., Moberg P.J., et.al. Antidepressant studies in Parkinsons disease: a review and
meta-analysis. // Mov.Dis.-2005.-Vol.20.-P.1161-1169.
54. Miyasaki J.M., Shannon K., Voon V., et.al. Practice parameter: evaluation and treatment of depression,
psychosis and dementia in Parkinsons disease (an evidence-based review):report of the Quality Standards
Subcommittee of the American Academy of Neurology. //Neurol.-2006.-Vol.66.-P.996-1002.
55.Devos D., Dujardin K., Poirot I., et.al. Comparison of desipramine and citalopram treatments with depression in
Parkinsons disease: a double-blind placebo-controlled study. //Mov.Dis.-2008.-Vol.23.-P.850-7.
56. I.H.Richard, M.P.McDermott, R.Kurlan et.al. A randomized, double –blind, placebo-controlled trial of
antidepressants in Parkinsons disease. //Neurol.-2012-Vol.11-N9.-P.26-34.
57. Menza M., Dobkin R.D., Marin H., et.al. A controlled trial of antidepressants in patients with Parkinsons
disease and depression. //Neurol.-2009.-Vol.72.-P.886-92
58. Mann J. J., Kapur S. A dopaminergic hypothesis of major depression. // Clin. Neuropharmacol. -1996. -Vol.
18(suppl. 1). -P. 57-65.
59.Barbeu A. L. L-Dopa therapy in Parkinson disease: a critical review of nine years experience. // J. Can. Med.
Assoc. -1969. -Vol. 101. -P. 791-800.
60. Нодель М.Р., Артемьев Д.В., Яхно Н.Н.. Эффективность дофаминового агониста Мирапекса при
болезни Паркинсона. // Неврологический журнал. - 1999. – N6. - С. 45-49.
61. Левин О.С., Федорова Н.В., Смоленцева И.Г. Применение агонистов дофаминовых рецепторов при
болезни Паркинсона.//Неврологический журнал- 2002. -№1. С.41-45.
62. Lemke M.P., Brecht H.M., Koester J.K., et.al. Anhedonia, depression, and motor functioning in Parkinsons
disease during treatment with Pramipexole. //J.Neuropsych.Clin.Neurosci-2005.-Vol.17.-P.2.-P.214-220.
63. Barone P., Poewe W., Tolosa E., et.al. Efficacy of double-blind, placebo-controlled pramipexole against
depression in Parkinsons disease. Abstracts of the Movement Disorders Societys Thirteenth International Congress
of Parkinson's disease and movement disorders. June 7-11-2009-Suppl.1 –P.291.
4.Schoenfeld M.A., Pantelie C.M., B. Schwartz . Clinical criteria for the switch of treatment strategies in
Parkinson’s disease. //Clinical Neurol. and Neurosurg. -2003.-Vol. 105.-P.241-244.